Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies

NCT00078195 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

168

Enrollment

NIH

Sponsor class

Conditions

Hay Fever
Hypersensitivity
Allergy
Rhinitis

Interventions

BIOLOGICAL: omalizumab
BIOLOGICAL: Placebo omalizumab
BIOLOGICAL: Ragweed rush immunotherapy (RIT)
BIOLOGICAL: Placebo rush immunotherapy (RIT)
BIOLOGICAL: Ragweed immunotherapy (IT)
BIOLOGICAL: Placebo immunotherapy (IT)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]